Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

ELISpot assay and prediction of organ transplant rejection

E. Girmanova, P. Hruba, O. Viklicky, A. Slavcev

. 2022 ; 49 (1) : 39-45. [pub] 20211215

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011153

Grantová podpora
NT/14022-3 the Ministry of Health of the Czech Republic
IN 00023001) MH CZ - DRO (Institute for Clinical and Experimental Medicine - IKEM

The ELISpot assay is a sensitive technique applied to assess cytokine-producing memory/effector T cells and human leukocyte antigens (HLA)-specific IgG-producing B cells. Besides the fact that the method is laborious and is difficult to standardise between laboratories, it may provide valuable information on the immune response of recipients before and after organ transplantation. In this article, we briefly review the recent literature and discuss the clinical significance of the ELISpot assay in predicting the risk and incidence of allograft rejection and survival.

000      
00000naa a2200000 a 4500
001      
bmc22011153
003      
CZ-PrNML
005      
20220506130429.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/iji.12565 $2 doi
035    __
$a (PubMed)34910357
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Girmanova, Eva $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
245    10
$a ELISpot assay and prediction of organ transplant rejection / $c E. Girmanova, P. Hruba, O. Viklicky, A. Slavcev
520    9_
$a The ELISpot assay is a sensitive technique applied to assess cytokine-producing memory/effector T cells and human leukocyte antigens (HLA)-specific IgG-producing B cells. Besides the fact that the method is laborious and is difficult to standardise between laboratories, it may provide valuable information on the immune response of recipients before and after organ transplantation. In this article, we briefly review the recent literature and discuss the clinical significance of the ELISpot assay in predicting the risk and incidence of allograft rejection and survival.
650    _2
$a ELISPOT $7 D058501
650    12
$a rejekce štěpu $7 D006084
650    _2
$a lidé $7 D006801
650    _2
$a interferon gama $7 D007371
650    12
$a transplantace ledvin $7 D016030
650    _2
$a T-lymfocyty $7 D013601
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Hruba, Petra $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Viklicky, Ondrej $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Department of Nephrology and Transplantation Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Slavcev, Antonij $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $1 https://orcid.org/0000000261549131 $7 xx0060517
773    0_
$w MED00008484 $t International journal of immunogenetics $x 1744-313X $g Roč. 49, č. 1 (2022), s. 39-45
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34910357 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130422 $b ABA008
999    __
$a ok $b bmc $g 1788975 $s 1162351
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 49 $c 1 $d 39-45 $e 20211215 $i 1744-313X $m International journal of immunogenetics $n Int J Immunogen $x MED00008484
GRA    __
$a NT/14022-3 $p the Ministry of Health of the Czech Republic
GRA    __
$a IN 00023001) $p MH CZ - DRO (Institute for Clinical and Experimental Medicine - IKEM
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace